{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:15:10Z","timestamp":1767903310271,"version":"3.49.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bcp.2024.116617","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T17:11:22Z","timestamp":1731172282000},"page":"116617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P3","title":["Evaluation of UCP1162, a potent propargyl-linked inhibitor of dihydrofolate reductase with potential application to cancer and autoimmune disease"],"prefix":"10.1016","volume":"230","author":[{"given":"Didem","family":"Ozcan Tezgin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Kurkcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debjani","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Krucinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriane","family":"Mosley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratik","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Babic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmar","family":"Nurmemmedov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig E","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis L.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.bcp.2024.116617_b0005","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber","year":"1948","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bcp.2024.116617_b0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.57.2.3","article-title":"Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis","volume":"57","author":"Cronstein","year":"2005","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bcp.2024.116617_b0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/B978-0-12-800223-0.00004-9","article-title":"Biology of the major facilitative folate transporters SLC19A1 and SLC46A1","volume":"73","author":"Hou","year":"2014","journal-title":"Curr Top Membr"},{"issue":"16","key":"10.1016\/j.bcp.2024.116617_b0020","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2165\/11202640-000000000-00000","article-title":"Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer","volume":"69","author":"Baldwin","year":"2009","journal-title":"Drugs"},{"issue":"31","key":"10.1016\/j.bcp.2024.116617_b0025","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.2174\/1381612033453712","article-title":"Anticancer antifolates: current status and future directions","volume":"9","author":"McGuire","year":"2003","journal-title":"Curr Pharm Des"},{"issue":"17","key":"10.1016\/j.bcp.2024.116617_b0030","doi-asserted-by":"crossref","first-page":"9720","DOI":"10.1016\/S0021-9258(17)39298-0","article-title":"Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates","volume":"260","author":"Allegra","year":"1985","journal-title":"J Biol Chem"},{"issue":"15","key":"10.1016\/j.bcp.2024.116617_b0035","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1073\/pnas.82.15.4881","article-title":"Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates","volume":"82","author":"Allegra","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.bcp.2024.116617_b0040","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/0006-2952(84)90192-8","article-title":"Enzymatic synthesis of polyglutamate derivatives of 7-hydroxymethotrexate","volume":"33","author":"McGuire","year":"1984","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.bcp.2024.116617_b0045","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1021\/jm00376a005","article-title":"A mechanism for the addition of multiple moles of glutamate by folylpolyglutamate synthetase","volume":"27","author":"Moran","year":"1984","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bcp.2024.116617_b0050","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0006-2952(95)00135-M","article-title":"Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line","volume":"50","author":"Lu","year":"1995","journal-title":"Biochem Pharmacol"},{"issue":"2 Suppl 6","key":"10.1016\/j.bcp.2024.116617_b0055","first-page":"42","article-title":"Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis","volume":"26","author":"Mendelsohn","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bcp.2024.116617_b0060","series-title":"Basel","author":"Cronstein","year":"2000"},{"key":"10.1016\/j.bcp.2024.116617_b0065","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.critrevonc.2016.08.001","article-title":"Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action","volume":"106","author":"Danenberg","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.bcp.2024.116617_b0070","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/00007691-199312000-00012","article-title":"Antifolate analogs: mechanism of action, analytical methodology, and clinical efficacy","volume":"15","author":"Fleisher","year":"1993","journal-title":"Ther Drug Monit"},{"issue":"Suppl 8","key":"10.1016\/j.bcp.2024.116617_b0075","first-page":"S101","article-title":"Antifolates in rheumatoid arthritis: a hypothetical mechanism of action","volume":"11","author":"Baggott","year":"1993","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2024.116617_b0080","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.30","article-title":"The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism","volume":"34","author":"Cronstein","year":"1995","journal-title":"Br J Rheumatol"},{"issue":"9","key":"10.1016\/j.bcp.2024.116617_b0085","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/ard.50.9.637","article-title":"In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine","volume":"50","author":"Nesher","year":"1991","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.bcp.2024.116617_b0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10555-007-9049-z","article-title":"Molecular basis of antifolate resistance","volume":"26","author":"Assaraf","year":"2007","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"10.1016\/j.bcp.2024.116617_b0095","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0925-5710(97)00058-3","article-title":"Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance","volume":"66","author":"Takemura","year":"1997","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bcp.2024.116617_b0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-015-0158-9","article-title":"Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia","volume":"8","author":"Wojtuszkiewicz","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.bcp.2024.116617_b0105","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V86.2.677.bloodjournal862677","article-title":"Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations","volume":"86","author":"Goker","year":"1995","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2024.116617_b0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance","volume":"15","author":"Gonen","year":"2012","journal-title":"Drug Resist Updat"},{"issue":"3","key":"10.1016\/j.bcp.2024.116617_b0115","doi-asserted-by":"crossref","DOI":"10.3390\/diseases12030063","article-title":"Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers","volume":"12","author":"Bharadwaj","year":"2024","journal-title":"Diseases"},{"issue":"24","key":"10.1016\/j.bcp.2024.116617_b0120","doi-asserted-by":"crossref","first-page":"16807","DOI":"10.18632\/oncotarget.24704","article-title":"Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer","volume":"9","author":"Tanino","year":"2018","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.bcp.2024.116617_b0125","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2217\/pgs-2019-0121","article-title":"Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis","volume":"20","author":"Jekic","year":"2019","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bcp.2024.116617_b0130","doi-asserted-by":"crossref","DOI":"10.2174\/0115733971285147240327051637","article-title":"Pharmacogenetic Basis of Response Fluctuations to Methotrexate in Rheumatoid Arthritis","author":"Qaisrani","year":"2024","journal-title":"A Narrative Review. Curr Rheumatol Rev"},{"issue":"6","key":"10.1016\/j.bcp.2024.116617_b0135","first-page":"562","article-title":"An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents","volume":"10","author":"Ranganathan","year":"2008","journal-title":"Curr Opin Mol Ther"},{"issue":"6","key":"10.1016\/j.bcp.2024.116617_b0140","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/13543776.2014.898062","article-title":"Antifolate agents: a patent review (2010\u20132013)","volume":"24","author":"Anderson","year":"2014","journal-title":"Expert Opin Ther Pat"},{"issue":"9","key":"10.1016\/j.bcp.2024.116617_b0145","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1517\/13543776.2011.587804","article-title":"Antifolate agents: a patent review (2006\u20132010)","volume":"21","author":"Wright","year":"2011","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"10.1016\/j.bcp.2024.116617_b0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrd.2015.18","article-title":"The drug-target residence time model: a 10-year retrospective","volume":"15","author":"Copeland","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.bcp.2024.116617_b0155","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrd2082","article-title":"Drug-target residence time and its implications for lead optimization","volume":"5","author":"Copeland","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.bcp.2024.116617_b0160","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1016\/S0021-9258(18)38101-8","article-title":"Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines","volume":"266","author":"McCloskey","year":"1991","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.bcp.2024.116617_b0165","first-page":"2149","article-title":"Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug","volume":"48","author":"Pizzorno","year":"1988","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.bcp.2024.116617_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10753-006-8962-6","article-title":"An interaction between genetic factors and gender determines the magnitude of the inflammatory response in the mouse air pouch model of acute inflammation","volume":"29","author":"Delano","year":"2005","journal-title":"Inflammation"},{"issue":"8","key":"10.1016\/j.bcp.2024.116617_b0175","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/art.1780380804","article-title":"The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine","volume":"38","author":"Cronstein","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.bcp.2024.116617_b0180","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bcp.2009.09.020","article-title":"DNA damage response to the Mdm2 inhibitor nutlin-3","volume":"79","author":"Verma","year":"2010","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"10.1016\/j.bcp.2024.116617_b0185","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"9","key":"10.1016\/j.bcp.2024.116617_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25094589","article-title":"Modification of Seurat v4 for the Development of a Phase Assignment Tool Able to Distinguish between G2 and Mitotic Cells","volume":"25","author":"Watson","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bcp.2024.116617_b0195","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1016\/j.csbj.2020.10.007","article-title":"Benchmarking algorithms for pathway activity transformation of single-cell RNA-seq data","volume":"18","author":"Zhang","year":"2020","journal-title":"Comput Struct Biotechnol J"},{"issue":"8","key":"10.1016\/j.bcp.2024.116617_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161740","article-title":"Propargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis","volume":"11","author":"Hajian","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.bcp.2024.116617_b0205","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/0006-2952(88)90359-0","article-title":"Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages","volume":"37","author":"Bokkerink","year":"1988","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.bcp.2024.116617_b0210","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/path.1711340205","article-title":"The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system","volume":"134","author":"Edwards","year":"1981","journal-title":"J Pathol"},{"key":"10.1016\/j.bcp.2024.116617_b0215","doi-asserted-by":"crossref","unstructured":"Duarte, D.B., M.R. Vasko, and J.C. Fehrenbacher, Models of inflammation: carrageenan air pouch. Curr Protoc Pharmacol, 2012. Chapter 5: p. Unit5 6.","DOI":"10.1002\/0471141755.ph0506s56"},{"issue":"6","key":"10.1016\/j.bcp.2024.116617_b0220","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1172\/JCI116884","article-title":"The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation","volume":"92","author":"Cronstein","year":"1993","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.bcp.2024.116617_b0225","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/art.40504","article-title":"Review: Synovial Cell Metabolism and Chronic Inflammation in Rheumatoid Arthritis","volume":"70","author":"Falconer","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"13","key":"10.1016\/j.bcp.2024.116617_b0230","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1182\/blood-2004-04-1493","article-title":"Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy","volume":"104","author":"Fotoohi","year":"2004","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bcp.2024.116617_b0235","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1182\/bloodadvances.2020001802","article-title":"CD200 expression marks leukemia stem cells in human AML","volume":"4","author":"Ho","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bcp.2024.116617_b0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/stem.200011","article-title":"ABC transporters as phenotypic markers and functional regulators of stem cells","volume":"20","author":"Bunting","year":"2002","journal-title":"Stem Cells"},{"issue":"12","key":"10.1016\/j.bcp.2024.116617_b0245","doi-asserted-by":"crossref","first-page":"6600","DOI":"10.1172\/JCI140797","article-title":"Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo","volume":"130","author":"Lopez-Lopez","year":"2020","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.bcp.2024.116617_b0250","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.V93.5.1677","article-title":"Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia","volume":"93","author":"Rots","year":"1999","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bcp.2024.116617_b0255","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood.V94.9.3121","article-title":"Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates","volume":"94","author":"Rots","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2024.116617_b0260","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/pgs.15.150","article-title":"Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients","volume":"17","author":"Moya","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bcp.2024.116617_b0265","doi-asserted-by":"crossref","first-page":"35615","DOI":"10.1038\/srep35615","article-title":"Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis","volume":"6","author":"Yamamoto","year":"2016","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.bcp.2024.116617_b0270","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm0901-1028","article-title":"The ABC transporter Bcrp1\/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype","volume":"7","author":"Zhou","year":"2001","journal-title":"Nat Med"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2024.116617_b0275","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00499119","article-title":"Localization of the gene for the vitamin B12 binding protein, transcobalamin II, near the centromere on mouse chromosome 11, linked with the hemoglobin alpha-chain locus","volume":"23","author":"Frater-Schroder","year":"1985","journal-title":"Biochem Genet"},{"issue":"9","key":"10.1016\/j.bcp.2024.116617_b0280","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ajmg.a.32199","article-title":"Nutritional and genetic determinants of vitamin B and homocysteine metabolisms in neural tube defects: a multicenter case-control study","volume":"146A","author":"Candito","year":"2008","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.bcp.2024.116617_b0285","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1046\/j.1523-1755.63.s84.52.x","article-title":"Genetic determinants of the homocysteine level","volume":"84","author":"Sunder-Plassmann","year":"2003","journal-title":"Kidney Int Suppl"},{"issue":"7","key":"10.1016\/j.bcp.2024.116617_b0290","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1084\/jem.20170484","article-title":"JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia","volume":"215","author":"Mansour","year":"2018","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.bcp.2024.116617_b0295","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00262-016-1917-3","article-title":"5T4 oncofoetal antigen: an attractive target for immune intervention in cancer","volume":"66","author":"Stern","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.bcp.2024.116617_b0300","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/1535-7163.MCT-11-0526","article-title":"Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions","volume":"11","author":"Ortenberg","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.bcp.2024.116617_b0305","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/imr.13272","article-title":"Type I interferon and cancer","volume":"321","author":"Holicek","year":"2024","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.bcp.2024.116617_b0310","first-page":"387","article-title":"Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril","volume":"24","author":"Stanojkovic","year":"2005","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.bcp.2024.116617_b0315","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/CAD.0000000000000112","article-title":"Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells","volume":"25","author":"Matsunaga","year":"2014","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bcp.2024.116617_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120596","article-title":"The oncogenic lysophosphatidylinositol (LPI)\/GPR55 signaling","volume":"301","author":"Calvillo-Robledo","year":"2022","journal-title":"Life Sci"},{"issue":"25","key":"10.1016\/j.bcp.2024.116617_b0325","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1021\/bi200010k","article-title":"Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands","volume":"50","author":"Kotsikorou","year":"2011","journal-title":"Biochemistry"},{"issue":"17","key":"10.1016\/j.bcp.2024.116617_b0330","doi-asserted-by":"crossref","first-page":"7417","DOI":"10.1021\/jm300841n","article-title":"Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library","volume":"55","author":"Brozic","year":"2012","journal-title":"J Med Chem"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224006178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224006178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T01:01:43Z","timestamp":1732928503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224006178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":66,"alternative-id":["S0006295224006178"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116617","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of UCP1162, a potent propargyl-linked inhibitor of dihydrofolate reductase with potential application to cancer and autoimmune disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116617"}}